5 Most Promising Cancer Stocks According to Analysts

In this piece, we will take a look at the five most promising cancer stocks according to analysts. If you want to learn all about the cancer treatment industry, then check out 12 Most Promising Cancer Stocks According to Analysts.

5. Theseus Pharmaceuticals, Inc. (NASDAQ:THRX)

Latest Analyst Share Price Upside: 82.13%

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) is developing treatments for stomal tumors and lung cancer. The firm’s shares gained more than 50% in November 2023 after it announced restructuring plans that impressed investors.

By the end of this year’s third quarter, nine out of the 910 hedge funds surveyed by Insider Monkey had bought and owned Theseus Pharmaceuticals, Inc. (NASDAQ:THRX)’s shares. Samuel Isaly’s OrbiMed Advisors was the biggest investor through its $47.6 million stake.

4. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Latest Analyst Share Price Upside: 83.11%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a small biotechnology company focusing on treatments for child cancers, tumors, and other ailments. December was a good month for the stock as it was added to the NASDAQ biotechnology index after meeting all the criteria for inclusion.

As of Q3 2023 end, 12 out of the 910 hedge funds profiled by Insider Monkey were the firm’s investors. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s largest hedge fund shareholder is Brian Ashford-Russell and Tim Woolley’s Polar Capital as it owns $11.4 million worth of shares.

3. Fate Therapeutics, Inc. (NASDAQ:FATE)

Latest Analyst Share Price Upside: 109.93%

Fate Therapeutics, Inc. (NASDAQ:FATE) develops treatments for lymphoma, myeloma, and solid tumors. It has performed well financially as of late by having beaten analyst EPS estimates in all four of its latest quarters. The shares are rated Buy on average, and the average share price target is $6.34.

Insider Monkey dug through 910 hedge fund portfolios for this year’s September quarter and discovered 24 Fate Therapeutics, Inc. (NASDAQ:FATE) shareholders. Jeremy Green’s Redmile Group was the biggest investor through its $27.8 million investment.

2. Kura Oncology, Inc. (NASDAQ:KURA)

Latest Analyst Share Price Upside: 128.05%

Kura Oncology, Inc. (NASDAQ:KURA) is a biotechnology firm developing treatments for leukemia, tumors, and liver disorders. The firm scored a win in December 2023 when its leukemia treatment allowed it to team with a major blood cancer research funder to further develop the drug.

During 2023’s third quarter, 21 out of the 910 hedge funds covered by Insider Monkey’s research had invested in the company. Kura Oncology, Inc. (NASDAQ:KURA)’s largest shareholder in our database is Aaron Cowen’s Suvretta Capital Management as it holds $66.9 million worth of shares.

1. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Latest Analyst Share Price Upside: 162.47%

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s treatments target a variety of cancers such as cervical cancer, lung cancer, and melanoma. The firm’s shares are rated Strong Buy on average and analysts have set an average share price target of $20.42.

31 out of the 910 hedge funds surveyed by Insider Monkey had held a stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) during Q3 2023. Mark Rachesky’s MHR Fund Management was the biggest investor through its $90.9 million investment.

Disclosure: None. You can also take a look at 11 Best Fundamentally Strong Penny Stocks To Invest In and 13 Best Holding Company Stocks To Invest In.

Follow Insider Monkey on Twitter